Relief Therapeutics Holding AG (RLFTF)

[MelsDollars]

I agree, interesting timing Bob1968. Lots of things coming together around the same time: lackluster 28 day IV data, determination that they needed to develop a more shelf stable IV product, etc. Perhaps Relief felt that the inhaled market was a quicker/better route to market and went in that direction instead. NeuroRX continued on with IV because they were mid-trial and waiting for 60 day data. Partnered with TFF for powdered version. Should be a win-win for everyone if any of these different formulations gets approved.